Acute graft versus host disease in intestine

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
4 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
HDAC inhibitor 1 substance
Kinase inhibitor 1 substance
Phase III: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Maat Pharma Commercial
    ALLOGENEIC FAECAL MICROBIOTA, POOLED
    2024-513023-17-00 6 countries 2022 n=73 Orphan
    Ended

Phase IV

1 trial
  • Novartis Pharma Services AG Commercial
    PANOBINOSTAT; RUXOLITINIB; SIREMADLIN
    2024-515283-31-00 4 countries 2015 n=33 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Maat Pharma Commercial 1 Phase III 0
Novartis Pharma Services AG Commercial 1 Phase IV 0
New trials by year
2022
1
← All indication landscapes